Clinical Trial Update: A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution [Phase 1]

View source ↗

Summary

Phase 1 study of [89Zr]-Oxine-NCR100 injection to assess cellular distribution in knee osteoarthritis is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Osteoarthritis

Drugs mentioned

• [89Zr]-Oxine-NCR100 injection

Snippet

Sponsor: Nuwacell Biotechnologies Co., Ltd. | Conditions: KOA | Phase 1 | Status: NOT_YET_RECRUITING